Humacyte Stock Today
| HUMA Stock | USD 1.00 0.03 2.91% |
PerformanceWeakest
| Odds Of DistressRisky
|
Humacyte is trading at 1.0 as of the 2nd of February 2026, a 2.91 percent decrease since the beginning of the trading day. The stock's open price was 1.03. Humacyte has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Note, on June 13, 2024, Senator Tommy Tuberville of US Senate acquired $15k to $50k worth of Humacyte's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of August 2021 | Category Healthcare | Classification Health Care |
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company was founded in 2004 and is headquartered in Durham, North Carolina. The company has 193 M outstanding shares of which 37.15 M shares are currently shorted by private and institutional investors with about 6.94 trading days to cover. More on Humacyte
Moving together with Humacyte Stock
Moving against Humacyte Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Humacyte Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsHumacyte can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Humacyte's financial leverage. It provides some insight into what part of Humacyte's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Humacyte (HUMA) is traded on NASDAQ Exchange in USA and employs 218 people. Humacyte is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 192.55 M. Humacyte conducts business under Biotechnology sector and is part of Health Care industry. The entity has 193 M outstanding shares of which 37.15 M shares are currently shorted by private and institutional investors with about 6.94 trading days to cover.
Humacyte currently holds about 189.04 M in cash with (98.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.84, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Humacyte Probability Of Bankruptcy
Ownership AllocationHumacyte has a total of 193 Million outstanding shares. Humacyte retains significant amount of outstanding shares owned by insiders and institutional investors . On June 13, 2024, Senator Tommy Tuberville of US Senate acquired $15k to $50k worth of Humacyte's common stock.
Check Humacyte Ownership Details
Humacyte Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2025-06-30 | 1.4 M | |
| Northern Trust Corp | 2025-06-30 | 1 M | |
| Private Advisor Group, Llc | 2025-06-30 | 1 M | |
| Charles Schwab Investment Management Inc | 2025-06-30 | 921.9 K | |
| Lpl Financial Corp | 2025-06-30 | 724.8 K | |
| Gsa Capital Partners Llp | 2025-06-30 | 643.7 K | |
| Goldman Sachs Group Inc | 2025-06-30 | 637.7 K | |
| Aqr Capital Management Llc | 2025-06-30 | 634.7 K | |
| Citadel Advisors Llc | 2025-06-30 | 624.8 K | |
| Blackrock Inc | 2025-06-30 | 9.9 M | |
| Vanguard Group Inc | 2025-06-30 | 7 M |
Humacyte Historical Income Statement
Humacyte Stock Against Markets
Humacyte Corporate Management
| Harold Alterson | Senior Quality | Profile | |
| Sabrina Osborne | Executive People | Profile | |
| Dale Sander | Chief CFO | Profile | |
| Heather Connelly | Senior Quality | Profile | |
| William Scheessele | Chief Officer | Profile | |
| Yang MD | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Humacyte. Market participants price Humacyte higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Humacyte assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.27) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Humacyte's market price often diverges from its book value, the accounting figure shown on Humacyte's balance sheet. Smart investors calculate Humacyte's intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Humacyte's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Humacyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Humacyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Humacyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.